Literature DB >> 20847376

Comparison in pathological behaviours & prognosis of gastric cancers from general hospitals between China & Japan.

Miao Yu1, Hua-chuan Zheng, Pu Xia, Hiroshi Takahashi, Shinji Masuda, Yasuo Takano, Hui-mian Xu.   

Abstract

BACKGROUND &
OBJECTIVES: Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related deaths after lung carcinoma. The aim of this study was to understand the difference in clinicopathological behaviours and prognosis of gastric cancer in patients from China and Japan.
METHODS: Paraffin-fixed tissue samples of gastric cancer were collected retrospectively from two hospitals between 1993 to 2006 in Japan (n=2063) and during 1980-2003 in China (n=2496) respectively, and staging was done by TNM system and typing by Japanese Endoscopy Society criteria or Borrmann's classification. The histological architecture of the tumours was expressed according to Lauren's classification.
RESULTS: Compared to Japan, the occurrence of gastric cancer was more common in younger Chinese population and prone to invasion and metastasis in muscularis propia, lymphatic, lymph node, liver, peritoneal parts, and exhibited large tumour size and high TNM staging in both the sexes and in different age groups (P<0.05). Intestinal and mixed types of carcinomas were more frequently observed in Japanese patients compared to Chinese and the difference was significant (P<0.05). It was observed that the commonly reported types in early gastric cancers (EGC) in Japanese patients were IIc, IIa+IIc or IIa while those of Chinese patients were IIc, III or IIb. In the case of advanced gastric cancers (AGC), type II and III were most common in both the countries. The cumulative survival rate of Chinese patients was significantly (P<0.05) higher compared to Japanese in different stratified groups via depth of invasion, TNM staging or Lauren's classification. INTERPRETATION &amp;
CONCLUSION: Gastric cancers in Chinese patients had more aggressive pathological characteristics and poorer prognosis than those from Japan. To reduce incidence and to improve treatment facilities, it is necessary to have a systematic screening system.

Entities:  

Mesh:

Year:  2010        PMID: 20847376

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  6 in total

1.  Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer.

Authors:  Kaixiong Tao; Chuanqing Wu; Ke Wu; Wei Li; Gaoxiong Han; Xiaoming Shuai; Guobin Wang
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

2.  Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer.

Authors:  Juan Yang; Xiaofan Xiong; Xiaofei Wang; Bo Guo; Kang He; Chen Huang
Journal:  Tumour Biol       Date:  2015-02-14

3.  Radiolabeling and evaluation of (64)Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer.

Authors:  Hua Zhu; Chuanke Zhao; Fei Liu; Lixin Wang; Junnan Feng; Zheng Zhou; Like Qu; Chengchao Shou; Zhi Yang
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 4.  Early brain metastasis of advanced gastric cancer with a pathological complete response to neoadjuvant chemotherapy followed by surgery: A case report and literature review.

Authors:  Hui Luo; Liangqun Peng; Nan Wang; Jiangong Zhang; Xiaoli Zheng; Yanan Sun; Chengcheng Fan; Hong Ge
Journal:  Cancer Biol Ther       Date:  2018-04-30       Impact factor: 4.742

5.  Significant differences in the clinicopathological characteristics and survival of gastric cancer patients from two cancer centers in china and Korea.

Authors:  Zhan Long Shen; Kyo Young Song; Ying Jiang Ye; Qi Wei Xie; Bin Liang; Kewei Jiang; Cho Hyun Park; Shan Wang
Journal:  J Gastric Cancer       Date:  2015-03       Impact factor: 3.720

6.  Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer.

Authors:  Xuechao Liu; Deyao Zhang; Enzi Lin; Yongming Chen; Wei Li; Yingbo Chen; Xiaowei Sun; Zhiwei Zhou
Journal:  BMC Cancer       Date:  2018-06-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.